“Considered by peers as ‘one of
the best generic Hatch-Waxman
litigation firms on the east coast.’”
– LMG Life Sciences
Visit our new blog at www.biosimilarsip.com
“Rothwell Figg is known for ‘meticulous patent drafting.’ Solely based in the capital, [Rothwell Figg] knows all the ins and outs of the D.C. scene and the USPTO.”
Post-Grant Trial Practice
“[This] compact yet heavy-hitting IP boutique has a client list that is the envy of many. Marquee names are drawn here for several compelling reasons: a persuasive win rate in high-stakes cases, the advanced technical backgrounds of its litigators, great comparative value and renowned expertise in post-grant procedures.”
Visit our new blog at www.ptablaw.com
Represented Mylan Pharmaceutical in an infringement claim made by Bristol-Myers Squibb related to the drug Buspar (buspirone).
Bristol-Myers motioned to dismiss antitrust counterclaims made by Mylan. The Court ruled a summary judgment of noninfringement. The court also denied Bristol’s motion and suing Mylan on it, as well as held that Bristol had acted in an objectively unreasonable fashion in listing the metabolite patent for buspirone in the Orange Book.
Bristol-Myers settled the antitrust claims by paying $535 million, including $35 million to Mylan after an initial ruling in favor of Mylan, 29 State Attorneys General, and several plaintiff class action groups who had joined Mylan’s suit.
company’s IP case
Patent troll CyberFone Systems LLC alleges Warner Bros. Entertainment Inc., CBS Interactive Inc., and dozens of other companies infringed a patent which covers a system of entering transaction data into databases because it covers an abstract concept rather than a specific invention.
The district court granted defendants motion for summary judgment that CyberFone’s patent was invalid under USC 101. Rothwell Figg took the lead in drafting and arguing the motion on behalf of the defendants. Rothwell Figg also took the lead in drafting and arguing against CyberFone’s appeal to the Federal Circuit.
February 2014, the three-judge Federal Circuit panel upheld the District of Delaware’s ruling that invalidated a software patent that CyberFone Systems LLC; alleged the 81 companies including CBS, CNN and Fox News infringed because it was not patent eligible under 35 USC 101.
Shaping a 360°
defense for leading
360° IP Performance
Rothwell Figg is a multifaceted intellectual property firm for high-stakes legal matters.
- Lisa Phillips at 2018 AIPF Annual Meeting
Partner Lisa Phillips will participate in a panel during the Association of Intellectual Property Firms (AIPF) 2018 Annual Meeting taking place September 27-28, 2018, in Chicago, Illinois. Ms. Phillips' panel, "Navigating Discovery in Patent Litigation," will take place on…
- 2018 Women, Influence & Power in Law Conference (WIPL)
Rothwell Figg is a proud sponsor of the Women, Influence & Power in Law Conference (WIPL) taking place October 4-5, 2018, in Washington, DC. WIPL is the original global forum facilitating women-to-women exchange on leadership and legal…
- Partner Steven Lieberman Quoted in Articles on Subpoena Challenge in Eichenwald Case
Partner Steven Lieberman is quoted in two articles, one from The Daily Record and one from Law360, on a Maryland federal judge's rejection of John Rivello's motion to quash subpoenas that Kurt Eichenwald sent to seven parties including…
- Partner R. Danny Huntington Once Again Named One of World’s Leading IP Strategists by IAM Strategy 300
Once again, partner R. Danny Huntington has been named among the world’s pre-eminent IP strategists in the latest edition of IAM Strategy 300 – The World’s Leading IP Strategists. The guide lists the individuals that…
- Alternative Dispute Resolution
- Biologics and Biosimilars
- Biology and Biotechnology
- Cybersecurity, Privacy, and Data Protection
- Electrical and Computer
- Food and Drug Administration Practice
- Hatch-Waxman Litigation
- International Trade Commission
- Licensing and Transactions
- Media and Financial Services
- Patent Prosecution
- Post-Grant Trial Practice
- Software, E-Commerce and Business Methods
- Trademark Trial and Appeal Board
- Unfair Competition